2756388-01-7
Chemical Structure
BSJ-05-037
- CAS No.: 2756388-01-7
- Formula:C51H59N9O10S2
- Molecular Weight:1022.20
InChIKey: WFVKDTWKNVLGGS-UHFFFAOYSA-N
SMILES: O=C(NC1=NC=C(SC2=CC(C(N3CCN(C(C)=O)CC3)=O)=C(OC)C=C2C)S1)C4=CC=C(N5CCN(CCCCCCCNC(COC6=C7C(C(N(C8CCC(NC8=O)=O)C7=O)=O)=CC=C6)=O)CC5)C=C4
Biological Activity: BSJ-05-037 is an ITK PROTAC degrader that effectively targets and degrades ITK in T-cell lymphoma cell lines. BSJ-05-037 blocks the activation of the NF-κB/GATA-3 signaling pathway, inhibits PLCγ1 phosphorylation, and reduces the proliferative capacity of T-cell lymphoma cells. BSJ-05-037 enhances the sensitivity of T-cell lymphoma cells to chemotherapy. In mouse models of T-cell lymphoma, BSJ-05-037 induces ITK degradation, reduces GATA-3 expression, decreases tumor volume, and reverses chemotherapy resistance. BSJ-05-037 is applicable to research related to T-cell lymphoma[1][2][3].
| Cat. No. | Nom du produit | Pureté | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
BSJ-05-037 | 99.83% | BSJ-05-037 is an ITK PROTAC degrader that effectively targets and degrades ITK in T-cell lymphoma cell lines. BSJ-05-037 blocks the activation of the NF-κB/GATA-3 signaling pathway, inhibits PLCγ1 phosphorylation, and reduces the proliferative capacity of T-cell lymphoma cells. BSJ-05-037 enhances the sensitivity of T-cell lymphoma cells to chemotherapy. In mouse models of T-cell lymphoma, BSJ-05-037 induces ITK degradation, reduces GATA-3 expression, decreases tumor volume, and reverses chemotherapy resistance. BSJ-05-037 is applicable to research related to T-cell lymphoma. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Jiang B, et al. ITK degradation to block T cell receptor signaling and overcome therapeutic resistance in T cell lymphomas. Cell Chem Biol. 2023;30(4):383-393.e6. [Content Brief]
- [2]. Tigu AB, et al. Proteolysis targeting chimeric-based technology in myeloma and lymphoma. Mol Cancer Ther. Published online January 2, 2026. [Content Brief]
- [3]. Miletić N, et al. Workflow for E3 Ligase Ligand Validation for PROTAC Development. ACS Chem Biol. 2025;20(2):507-521. [Content Brief]
